Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azilsartan medoxomil - Takeda

Drug Profile

Azilsartan medoxomil - Takeda

Alternative Names: Azilsartan kamedoxomil; Azilsartan medoxomil potassium; Edarbi; Ipreziv; TAK-491

Latest Information Update: 17 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Antihypertensives; Benzimidazoles; Small molecules
  • Mechanism of Action Angiotensin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypertension(In adolescents, In children, In infants) in United Kingdom (PO, Tablet)
  • 08 Oct 2017 Takeda completes a phase III trial for Hypertension in China (PO) (NCT02480764)
  • 01 Feb 2016 Takeda completes a phase III trial in Hypertension in South Korea (NCT02203916)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top